Neuroscience
Amyloid Precursor Protein
90%
Pimavanserin
90%
Receptor
90%
Neurite Outgrowth
90%
Brain Disease
90%
Prasinezumab
90%
Tourette Syndrome
90%
Behavioral Therapy
90%
Status Epilepticus
90%
Ziprasidone
45%
Aripiprazole
45%
Lipoprotein Receptor-Related Protein
36%
Diffusion MRI
15%
Protein Interaction
12%
Placebo
9%
Hallucination
9%
Inverse Agonist
9%
5-HT2A Receptor
9%
Parkinson's Disease
9%
Serotonin
9%
Delusion
9%
Posttranslational Modification
6%
Mitogen Activated Protein Kinase 1
6%
In Vitro
6%
Protein Binding
6%
Endocytosis
6%
Low Density Lipoprotein Receptor Related Protein
6%
Hippocampus
6%
Pharmacology, Toxicology and Pharmaceutical Science
Parkinson's Disease
100%
Pimavanserin
90%
Neurotoxicity
90%
Controlled Clinical Trial
90%
Aztreonam
90%
Gilles De La Tourette Syndrome
90%
Prasinezumab
90%
Brain Disease
45%
Beta Lactam Antibiotic
45%
Beta Lactam
45%
Tic
45%
4 Aminobutyric Acid Receptor
22%
Bullous Pemphigoid
22%
Acute Kidney Failure
22%
Drug Toxicity
22%
Cystitis
22%
Ziprasidone
15%
Clinical Trial
11%
Serotonin 2A Receptor
9%
Placebo
9%
Side Effect
9%
Hallucination
9%
Adverse Event
9%
Serotonin
9%
Inverse Agonist
9%
Keyphrases
Home Video
90%
Subacute Encephalopathy
90%
Interactive Mobile Application
90%
Cannabis Products
45%
Type II Inhibitor
45%
Ziprasidone
45%
Target Selection
45%
Tic Severity
40%
Cell Diagnostics
30%
Levodopa-carbidopa Intestinal Gel
30%
β-lactam Ring
22%
Yale Global Tic Severity Scale (YGTSS)
20%
Antiseizure
18%
Reversible Diffusions
18%
EEG Correlates
18%
Video Database
11%
Home Recording
11%
DAT-SPECT Imaging
11%
Standard Time
11%
AD Therapy
6%
Dendritic Outgrowth
6%
